Young E. Whang

7.6k total citations · 2 hit papers
101 papers, 5.6k citations indexed

About

Young E. Whang is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Young E. Whang has authored 101 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 42 papers in Molecular Biology and 39 papers in Oncology. Recurrent topics in Young E. Whang's work include Prostate Cancer Treatment and Research (45 papers), PI3K/AKT/mTOR signaling in cancer (18 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). Young E. Whang is often cited by papers focused on Prostate Cancer Treatment and Research (45 papers), PI3K/AKT/mTOR signaling in cancer (18 papers) and Radiopharmaceutical Chemistry and Applications (11 papers). Young E. Whang collaborates with scholars based in United States, United Kingdom and Germany. Young E. Whang's co-authors include Charles L. Sawyers, Xinyi Wu, Elliott Kieff, H. Shelton Earp, Mehran S. Neshat, James L. Mohler, Jerome E. Tanner, Xiu‐Juan Yuan, Douglas T. Fearon and Janis J. Weis and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Young E. Whang

95 papers receiving 5.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

1998 539 citations Young E. Whang, Charles L. Sawyers et al. Proceedings of the National Academy of Sciences profile →
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

1998 526 citations Young E. Whang, Charles L. Sawyers et al. Proceedings of the National Academy of Sciences profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Young E. Whang	3.2k	1.7k	1.5k	874	604	101	5.6k
S. Gail Eckhardt	2.6k 0.8×	2.5k 1.5×	1.1k 0.7×	1.2k 1.3×	624 1.0×	105	5.3k
Lee Goodglick	2.6k 0.8×	1.5k 0.9×	1.5k 1.0×	804 0.9×	889 1.5×	98	5.5k
Miguel A. Villalona‐Calero	2.7k 0.9×	3.2k 1.9×	2.1k 1.4×	1.1k 1.2×	384 0.6×	187	6.4k
Devalingam Mahalingam	2.9k 0.9×	2.0k 1.2×	711 0.5×	922 1.1×	655 1.1×	186	5.4k
Tesshi Yamada	4.3k 1.4×	2.7k 1.6×	2.0k 1.3×	1.3k 1.5×	558 0.9×	141	8.3k
Jonathan M. Kurie	3.2k 1.0×	1.9k 1.1×	1.2k 0.8×	998 1.1×	691 1.1×	101	5.3k
Filip Lardon	2.9k 0.9×	2.7k 1.6×	976 0.6×	1.2k 1.4×	1.5k 2.5×	170	6.4k
Paul D. Smith	5.1k 1.6×	2.4k 1.5×	1.4k 0.9×	1.4k 1.6×	553 0.9×	120	7.5k
Marcella Mottolese	3.5k 1.1×	3.1k 1.8×	916 0.6×	1.5k 1.8×	798 1.3×	224	7.2k
Monica Mita	4.5k 1.4×	3.6k 2.1×	1.9k 1.2×	1.2k 1.3×	845 1.4×	239	8.2k

Countries citing papers authored by Young E. Whang

Since Specialization

Citations

This map shows the geographic impact of Young E. Whang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Young E. Whang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Young E. Whang more than expected).

Fields of papers citing papers by Young E. Whang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Young E. Whang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Young E. Whang. The network helps show where Young E. Whang may publish in the future.

Co-authorship network of co-authors of Young E. Whang

This figure shows the co-authorship network connecting the top 25 collaborators of Young E. Whang. A scholar is included among the top collaborators of Young E. Whang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Young E. Whang. Young E. Whang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tran, Ben, Kevin D. Courtney, Alexandra Sokolova, et al.. (2025). A phase 1b, open-label, multicenter study of xaluritamig in patients with biochemical recurrence of prostate cancer after definitive therapy.. Journal of Clinical Oncology. 43(5_suppl).

Patel, Shetal, Young E. Whang, Kevin Chen, et al.. (2024). Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report. JTO Clinical and Research Reports. 5(10). 100712–100712. 5 indexed citations

Kumar, Vaibhav, Nathan D. Montgomery, Hendrik W. van Deventer, & Young E. Whang. (2023). Waldenström macroglobulinemia with secondary pure red cell aplasia in a patient with metastatic castrate resistant prostate cancer receiving an immune checkpoint inhibitor: a case report. Journal of Medical Case Reports. 17(1). 220–220. 1 indexed citations

Hanson, Erik D., Alexander R. Lucas, Young E. Whang, et al.. (2022). Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. 26(2). 302–308. 11 indexed citations

Naqash, Abdul Rafeh, et al.. (2019). Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. Journal for ImmunoTherapy of Cancer. 7(1). 4–4. 17 indexed citations

Siddiqui, Salma, Benjamin A. Mooso, Leandro S. D’Abronzo, et al.. (2019). Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. British Journal of Cancer. 121(3). 237–248. 20 indexed citations

Rose, Tracy L., David D. Chism, Ajjai Alva, et al.. (2018). Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. British Journal of Cancer. 119(7). 801–807. 28 indexed citations

Shore, Neal D., Elisabeth I. Heath, Luke T. Nordquist, et al.. (2017). Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Annals of Oncology. 28. v272–v272. 1 indexed citations

Karaca, Mehmet, Yuanbo Liu, Zhentao Zhang, et al.. (2015). Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. PLoS ONE. 10(5). e0126270–e0126270. 13 indexed citations

10.

Hudes, Gary R., Scott T. Tagawa, Young E. Whang, et al.. (2012). A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer. Investigational New Drugs. 31(3). 669–676. 54 indexed citations

11.

Whang, Young E., Andrew J. Armstrong, W. Kimryn Rathmell, et al.. (2011). A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 31(1). 82–86. 69 indexed citations

12.

Mahajan, Nupam P., Yuanbo Liu, Samarpan Majumder, et al.. (2007). Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proceedings of the National Academy of Sciences. 104(20). 8438–8443. 197 indexed citations

13.

Mahajan, Nupam P., Young E. Whang, James L. Mohler, & H. Shelton Earp. (2005). Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox. Cancer Research. 65(22). 10514–10523. 176 indexed citations

14.

Gregory, Christopher W., Young E. Whang, Yuanbo Liu, et al.. (2005). Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth. Clinical Cancer Research. 11(5). 1704–1712. 107 indexed citations

15.

Liu, Yuanbo, Samarpan Majumder, Carolyn I. Sartor, et al.. (2005). Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer. Cancer Research. 65(8). 3404–3409. 71 indexed citations

16.

Zhou, Chunxiao, Victoria Bae‐Jump, Young E. Whang, Paola A. Gehrig, & John F. Boggess. (2005). The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels. Gynecologic Oncology. 101(2). 305–310. 44 indexed citations

17.

Nan, Bicheng, et al.. (2003). The PTEN tumor suppressor is a negative modulator of androgen receptor transcriptional activity. Journal of Molecular Endocrinology. 31(1). 169–183. 52 indexed citations

18.

Calvo, Benjamin F., Qu Fan Collins, Mary Iacocca, et al.. (2003). Human epidermal receptor-2 expression in prostate cancer.. PubMed. 9(3). 1087–97. 54 indexed citations

19.

Mayo, Marty W., Lee V. Madrid, Sandy D. Westerheide, et al.. (2002). PTEN Blocks Tumor Necrosis Factor-induced NF-κB-dependent Transcription by Inhibiting the Transactivation Potential of the p65 Subunit. Journal of Biological Chemistry. 277(13). 11116–11125. 107 indexed citations

20.

Yuan, Zhi-Min, Yinyin Huang, Young E. Whang, et al.. (1996). Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature. 382(6588). 272–274. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact